Kancera Targets COVID-19 With Fractalkine Inhibitor

CEO Hopes Phase II Trial Will Advance KAND567

 
• By Sten Stovall
  
KAND567 may prevent damaging infiltration of immune cells into lung tissue • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D